Novel
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
17
05
2023
pmc-release:
03
07
2024
medline:
20
7
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Despite intensive efforts, no inhibitors of the Wnt/β-catenin signaling pathway have been approved so far for the clinical treatment of cancer. We synthesized novel
Identifiants
pubmed: 37470018
doi: 10.1021/acsptsci.3c00092
pmc: PMC10353061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1087-1103Informations de copyright
© 2023 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Med Chem. 2022 May 26;65(10):7246-7261
pubmed: 35581674
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
J Med Chem. 2002 Jun 6;45(12):2615-23
pubmed: 12036371
J Comput Aided Mol Des. 2013 May;27(5):389-402
pubmed: 23737238
Science. 1997 Mar 21;275(5307):1787-90
pubmed: 9065402
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Cell Rep. 2020 Feb 11;30(6):1735-1752.e7
pubmed: 32049007
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Molecules. 2021 Dec 09;26(24):
pubmed: 34946546
Lab Invest. 1995 Dec;73(6):922-6
pubmed: 8558855
J Clin Oncol. 2005 Oct 10;23(29):7350-60
pubmed: 16145060
Mol Med Rep. 2015 Mar;11(3):1566-72
pubmed: 25384676
Science. 1997 Mar 21;275(5307):1784-7
pubmed: 9065401
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
J Med Chem. 2011 Dec 22;54(24):8394-406
pubmed: 22044164
Oncotarget. 2017 May 16;8(20):33972-33989
pubmed: 28430641
ChemMedChem. 2021 May 6;16(9):1420-1424
pubmed: 33275320
Eur J Med Chem. 2018 Aug 5;156:554-562
pubmed: 30025349
Nat Rev Drug Discov. 2017 Aug;16(8):525-526
pubmed: 28529321
Anticancer Res. 2019 Dec;39(12):6575-6583
pubmed: 31810923
Oncogenesis. 2019 Nov 4;8(11):64
pubmed: 31685809
Hum Mutat. 1993;2(6):425-34
pubmed: 8111410
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
pubmed: 9757107
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Cancers (Basel). 2022 Mar 07;14(5):
pubmed: 35267666
Cell. 2012 Jun 8;149(6):1245-56
pubmed: 22682247
J Med Chem. 2023 Jan 12;66(1):1-31
pubmed: 36583662
Mol Cell. 2004 Aug 27;15(4):523-33
pubmed: 15327769
J Immunol Methods. 1991 Sep 13;142(2):257-65
pubmed: 1919029
Biotechniques. 1991 Nov;11(5):620-7
pubmed: 1804254
BMC Cancer. 2020 Oct 28;20(1):1038
pubmed: 33115416
Trends Biochem Sci. 2018 Aug;43(8):623-634
pubmed: 30056837
Cell Rep. 2016 Jun 28;16(1):28-36
pubmed: 27320923
ACS Chem Biol. 2013 Mar 15;8(3):524-9
pubmed: 23272635
Science. 2014 Oct 3;346(6205):1248012
pubmed: 25278615
Bioinformatics. 2020 May 1;36(9):2909-2911
pubmed: 31930403
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Heliyon. 2021 Apr 12;7(4):e06695
pubmed: 33912703
Oncol Lett. 2014 Aug;8(2):699-704
pubmed: 25013487
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
J Med Chem. 2022 Nov 10;65(21):14261-14275
pubmed: 36282210
Methods Mol Biol. 2011;731:237-45
pubmed: 21516412
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
ACS Med Chem Lett. 2019 Jan 14;10(4):499-503
pubmed: 30996786
Exp Biol Med (Maywood). 2017 Jun;242(11):1185-1197
pubmed: 28474989
BMC Cancer. 2018 Mar 9;18(1):272
pubmed: 29523110
Mol Cancer Ther. 2008 Mar;7(3):521-9
pubmed: 18347139
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Oncogene. 2018 Jun;37(24):3301-3316
pubmed: 29551770
Oncol Lett. 2017 Jul;14(1):441-446
pubmed: 28693189
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
J Biol Chem. 1999 Jul 2;274(27):19115-23
pubmed: 10383415
ChemMedChem. 2020 Dec 3;15(23):2264-2268
pubmed: 32946182
Eur J Med Chem. 2015 May 5;95:277-301
pubmed: 25827398
J Hematol Oncol. 2020 Dec 4;13(1):165
pubmed: 33276800
J Biol Chem. 2003 Jun 6;278(23):21092-8
pubmed: 12657632